JP2022036976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022036976A5 JP2022036976A5 JP2021188305A JP2021188305A JP2022036976A5 JP 2022036976 A5 JP2022036976 A5 JP 2022036976A5 JP 2021188305 A JP2021188305 A JP 2021188305A JP 2021188305 A JP2021188305 A JP 2021188305A JP 2022036976 A5 JP2022036976 A5 JP 2022036976A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- car
- binding domain
- domain
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- LNXLHAWHHNDIDC-QFIPXVFZSA-N (2s)-2-[3-(hexadecanoylamino)propanoylamino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 LNXLHAWHHNDIDC-QFIPXVFZSA-N 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 8
- 230000003834 intracellular effect Effects 0.000 claims 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100039534 Calcium-activated chloride channel regulator 4 Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 2
- 102000017691 GABRA6 Human genes 0.000 claims 2
- 101710170439 Glycoprotein 2a Proteins 0.000 claims 2
- 102000017679 HTR3A Human genes 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 claims 2
- 101000888577 Homo sapiens Calcium-activated chloride channel regulator 4 Proteins 0.000 claims 2
- 101001001400 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-6 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101000688216 Homo sapiens Intestinal-type alkaline phosphatase Proteins 0.000 claims 2
- 101001004865 Homo sapiens Leucine-rich repeat-containing protein 26 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000615650 Homo sapiens MAM domain-containing glycosylphosphatidylinositol anchor protein 1 Proteins 0.000 claims 2
- 101000986598 Homo sapiens Mas-related G-protein coupled receptor member X3 Proteins 0.000 claims 2
- 101000991618 Homo sapiens Meprin A subunit beta Proteins 0.000 claims 2
- 101001133088 Homo sapiens Mucin-21 Proteins 0.000 claims 2
- 101000753535 Homo sapiens Potassium-transporting ATPase subunit beta Proteins 0.000 claims 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 2
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims 2
- 101000896517 Homo sapiens Steroid 17-alpha-hydroxylase/17,20 lyase Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims 2
- 101000897407 Homo sapiens T-cell surface glycoprotein CD1e, membrane-associated Proteins 0.000 claims 2
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims 2
- 101000598054 Homo sapiens Transmembrane protease serine 11B Proteins 0.000 claims 2
- 101000851563 Homo sapiens Transmembrane protein 211 Proteins 0.000 claims 2
- 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 claims 2
- 101000818870 Homo sapiens Zona pellucida sperm-binding protein 2 Proteins 0.000 claims 2
- -1 ICOS Proteins 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100025950 Leucine-rich repeat-containing protein 26 Human genes 0.000 claims 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims 2
- 102100023117 Long-chain fatty acid transport protein 6 Human genes 0.000 claims 2
- 102100021318 MAM domain-containing glycosylphosphatidylinositol anchor protein 1 Human genes 0.000 claims 2
- 102100028178 Mas-related G-protein coupled receptor member X3 Human genes 0.000 claims 2
- 102100030876 Meprin A subunit beta Human genes 0.000 claims 2
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 claims 2
- 102100034260 Mucin-21 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 claims 2
- 102100021944 Potassium-transporting ATPase subunit beta Human genes 0.000 claims 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 2
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims 2
- 108091006528 SLC27A6 Proteins 0.000 claims 2
- 102000005038 SLC6A4 Human genes 0.000 claims 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims 2
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100036014 T-cell surface glycoprotein CD1c Human genes 0.000 claims 2
- 102100021989 T-cell surface glycoprotein CD1e, membrane-associated Human genes 0.000 claims 2
- 102100026966 Thrombomodulin Human genes 0.000 claims 2
- 102100037023 Transmembrane protease serine 11B Human genes 0.000 claims 2
- 102100036759 Transmembrane protein 211 Human genes 0.000 claims 2
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 claims 2
- 102100021422 Zona pellucida sperm-binding protein 2 Human genes 0.000 claims 2
- 101000779569 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) Alkaline phosphatase PhoD Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 2
- 108091008042 inhibitory receptors Proteins 0.000 claims 2
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100024530 Carcinoembryonic antigen-related cell adhesion molecule 20 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000981108 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 20 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000764620 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 102100025096 Mesothelin Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100023125 Mucin-17 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100026243 Transmembrane and immunoglobulin domain-containing protein 1 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078927P | 2014-11-12 | 2014-11-12 | |
| US62/078,927 | 2014-11-12 | ||
| US201462081960P | 2014-11-19 | 2014-11-19 | |
| US62/081,960 | 2014-11-19 | ||
| JP2017525517A JP7023708B2 (ja) | 2014-11-12 | 2015-11-09 | 阻害性キメラ抗原受容体 |
| PCT/IB2015/058650 WO2016075612A1 (en) | 2014-11-12 | 2015-11-09 | Inhibitory chimeric antigen receptors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525517A Division JP7023708B2 (ja) | 2014-11-12 | 2015-11-09 | 阻害性キメラ抗原受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022036976A JP2022036976A (ja) | 2022-03-08 |
| JP2022036976A5 true JP2022036976A5 (https=) | 2022-06-28 |
Family
ID=54695797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525517A Active JP7023708B2 (ja) | 2014-11-12 | 2015-11-09 | 阻害性キメラ抗原受容体 |
| JP2021188305A Pending JP2022036976A (ja) | 2014-11-12 | 2021-11-19 | 阻害性キメラ抗原受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525517A Active JP7023708B2 (ja) | 2014-11-12 | 2015-11-09 | 阻害性キメラ抗原受容体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11072644B2 (https=) |
| EP (1) | EP3218394A1 (https=) |
| JP (2) | JP7023708B2 (https=) |
| AU (1) | AU2015344769B2 (https=) |
| CA (1) | CA2967222C (https=) |
| WO (1) | WO2016075612A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104955837A (zh) * | 2012-11-12 | 2015-09-30 | 海德堡吕布莱希特-卡尔斯大学 | Hbv和/或hdv易感细胞、细胞系和非人动物的开发 |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| EP3988111A1 (en) | 2016-04-01 | 2022-04-27 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| CA3025516A1 (en) * | 2016-05-27 | 2017-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
| BR112019006006A2 (pt) * | 2016-09-28 | 2019-06-25 | Gavish-Galilee Bio Applications Ltd. | molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico. |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| US20190358263A1 (en) * | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| SG10202108528QA (en) | 2017-06-02 | 2021-09-29 | Pfizer | Chimeric antigen receptors targeting flt3 |
| WO2019068007A1 (en) | 2017-09-28 | 2019-04-04 | Immpact-Bio Ltd. | UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR) |
| US20190338244A1 (en) * | 2017-11-30 | 2019-11-07 | New York Medical College | Multipotent adult stem cells: characterization and use |
| JP7416695B2 (ja) | 2017-12-29 | 2024-01-17 | メモリアル スローン－ケタリング キャンサー センター | 増強されたキメラ抗原受容体およびその使用 |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| BR112021006100A2 (pt) * | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| WO2020070290A1 (en) | 2018-10-05 | 2020-04-09 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| EP3632461A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| JP2022546315A (ja) * | 2019-08-20 | 2022-11-04 | センティ バイオサイエンシズ インコーポレイテッド | キメラ抑制性受容体 |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| EP4041893A4 (en) * | 2019-10-08 | 2023-08-30 | Provincial Health Services Authority | CHEMERACY CYTOKINE RECEPTORS |
| EP4058561A1 (en) | 2019-11-12 | 2022-09-21 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| CN115052887B (zh) * | 2019-12-11 | 2026-03-31 | A2生物治疗公司 | 基于lilrb1的嵌合抗原受体 |
| EP4107175A4 (en) * | 2020-02-20 | 2024-03-20 | Senti Biosciences, Inc. | ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS |
| CN115298209A (zh) * | 2020-02-20 | 2022-11-04 | 森迪生物科学公司 | 抑制性嵌合受体构造体 |
| GB202004832D0 (en) * | 2020-04-01 | 2020-05-13 | Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa | Therapeutic agaents, pharmaceutical compositions, and associated biomarkers |
| WO2022040444A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| US20220090013A1 (en) * | 2020-09-21 | 2022-03-24 | A2 Biotherapeutics, Inc. | Engineering immune cells based on antigen levels |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| CA3213040A1 (en) * | 2021-03-22 | 2022-09-29 | Michel Sadelain | Cd38 chimeric co-stimulating receptor and uses thereof |
| WO2022204326A1 (en) * | 2021-03-24 | 2022-09-29 | The Regents Of The University Of California | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
| WO2022251377A1 (en) * | 2021-05-26 | 2022-12-01 | Board Of Regents, The University Of Texas System | Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy |
| CN115028682B (zh) * | 2022-06-30 | 2025-06-06 | 合肥工业大学 | 一种来源于干腌火腿的增咸肽及制备方法 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| CN119506295B (zh) * | 2025-01-21 | 2025-05-30 | 上海皓鸿生物医药科技有限公司 | 一种前列腺特异性膜抗原的制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US9307495B2 (en) | 2011-09-12 | 2016-04-05 | Apple Inc. | Monitoring a battery in a portable electronic device |
| IL311390A (en) * | 2013-03-15 | 2024-05-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| KR102624023B1 (ko) * | 2015-02-24 | 2024-01-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 결합-촉발된 전사 스위치 및 이들의 이용 방법 |
| WO2017025323A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| BR112019006006A2 (pt) * | 2016-09-28 | 2019-06-25 | Gavish-Galilee Bio Applications Ltd. | molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico. |
| US12049482B2 (en) * | 2017-10-31 | 2024-07-30 | The Brigham And Women's Hospital, Inc. | Molecular switch-mediated control of engineered cells |
| WO2021173442A1 (en) * | 2020-02-24 | 2021-09-02 | The Regents Of The University Of California | In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells |
-
2015
- 2015-11-09 WO PCT/IB2015/058650 patent/WO2016075612A1/en not_active Ceased
- 2015-11-09 JP JP2017525517A patent/JP7023708B2/ja active Active
- 2015-11-09 AU AU2015344769A patent/AU2015344769B2/en active Active
- 2015-11-09 CA CA2967222A patent/CA2967222C/en active Active
- 2015-11-09 US US15/525,906 patent/US11072644B2/en active Active
- 2015-11-09 EP EP15798238.0A patent/EP3218394A1/en not_active Ceased
-
2021
- 2021-07-26 US US17/385,805 patent/US20220033462A1/en not_active Abandoned
- 2021-11-19 JP JP2021188305A patent/JP2022036976A/ja active Pending
-
2024
- 2024-03-15 US US18/607,387 patent/US20240360196A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022036976A5 (https=) | ||
| JP2022109975A5 (https=) | ||
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| Li et al. | A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer | |
| JP2022548796A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2024534417A5 (https=) | ||
| US20240342283A1 (en) | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | |
| JP2021525524A5 (https=) | ||
| HRP20250135T1 (hr) | Notch receptori sa zglobnom domenom | |
| JP2021536265A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2024534471A5 (https=) | ||
| JP2019537433A5 (https=) | ||
| JP2021520788A5 (https=) | ||
| GB2607452A (en) | Anti-TCR antibody molecules and uses thereof | |
| JP2013519379A5 (https=) | ||
| CN104592392B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| HRP20220767T1 (hr) | Liječenje raka uporabom humaniziranog kimernog receptora antigena anti-cd19 | |
| JP2021514631A5 (https=) | ||
| JP2023507729A5 (https=) | ||
| Shin et al. | Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy | |
| JP2022524906A (ja) | 細胞免疫療法の組み合わせ | |
| JP2024511423A5 (https=) | ||
| Stamova et al. | Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses |